# US 2026/0097010 A1 · Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097010 A1
- Document ID: US20260097010A1
- Status: Published application
- Kind: A1
- Application number: 19/418,323
- Filed: 2025-12-12
- Published: 2026-04-09
- Earliest claimed: 2016-07-22
- Assignees: Flamel Ireland Limited
- Applicants: Flamel Ireland Limited
- Inventors: Claire Mégret; Hervé Guillard; Jean-François Dubuisson; Jordan Dubow
- Web page: https://patentgrep.com/patent/US20260097010A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

## Claims

### Claim 1

A method of titrating a dose of a formulation for a human patient in need thereof, comprising adjusting the dose by about 1.5 g at weekly intervals, wherein the formulation is a powder suitable for administration to a human patient in need thereof, wherein the dose is equivalent to from 3.0 to 12.0 g of sodium oxybate, wherein the dose achieves a relative bioavailability (RBA) of greater than 85%, and wherein the formulation is suitable for administration once daily.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dose is equivalent to 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g, or 12.0 g of sodium oxybate.

### Claim 3 (depends on 1)

The method of claim 1, where in the powder is suitable for reconstitution as a suspension.

### Claim 4 (depends on 1)

The method of claim 1, where in the powder is suitable for oral administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dose achieves a relative bioavailability (RBA) of greater than 90%.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dose achieves a relative bioavailability (RBA) of greater than 95%.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dose achieves a relative bioavailability (RBA) of 100%.
